| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Microbiology, Immunology, and Pathology and
Department of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital, Cincinnati, OH 45229;
Integrated Department of Immunology, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center, Denver, CO 80206; and
Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80523
Complexing TLR9 agonists such as plasmid DNA to cationic liposomes markedly potentiates their ability to activate innate immunity. We therefore reasoned that liposomes complexed with DNA or other TLR agonists could be used as effective vaccine adjuvants. To test this hypothesis, the vaccine adjuvant effects of liposomes complexed to TLR agonists were assessed in mice. We found that liposomes complexed to nucleic acids (liposome-Ag-nucleic acid complexes; LANAC) were particularly effective adjuvants for eliciting CD4+ and CD8+ T cell responses against peptide and protein Ags. Notably, LANAC containing TLR3 or TLR9 agonists effectively cross-primed CD8+ T cell responses against even low doses of protein Ags, and this effect was independent of CD4+ T cell help. Ag-specific CD8+ T cells elicited by LANAC adjuvants were functionally active and persisted for long periods of time in tissues. In a therapeutic tumor vaccine model, immunization with the melanoma peptide trp2 and LANAC adjuvant controlled the growth of established B16 melanoma tumors. In a prophylactic vaccine model, immunization with the Mycobacterium tuberculosis protein ESAT-6 with LANAC adjuvant elicited significant protective immunity against aerosol challenge with virulent M. tuberculosis. These results suggest that certain TLR agonists can be combined with cationic liposomes to produce uniquely effective vaccine adjuvants capable of eliciting strong T cell responses against protein and peptide Ags.
This article has been cited by other articles:
|
|
 |
|
  K. Takeda, S. W. Dow, N. Miyahara, T. Kodama, T. Koya, C. Taube, A. Joetham, J.-W. Park, A. Dakhama, R. M. Kedl, et al. Vaccine-Induced CD8+ T Cell-Dependent Suppression of Airway Hyperresponsiveness and Inflammation J. Immunol., July 1, 2009; 183(1): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Bernstein, R. D. Cardin, F. J. Bravo, J. E. Strasser, N. Farley, C. Chalk, M. Lay, and J. Fairman Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines Clin. Vaccine Immunol., May 1, 2009; 16(5): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Kaminski, K. R. Turbyfill, C. Chao, W. M. Ching, and E. V. Oaks Mucosal Adjuvanticity of a Shigella Invasin Complex with DNA-Based Vaccines Clin. Vaccine Immunol., April 1, 2009; 16(4): 574 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. M. Grauer, J. W. Molling, E. Bennink, L. W. J. Toonen, R. P. M. Sutmuller, S. Nierkens, and G. J. Adema TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas J. Immunol., November 15, 2008; 181(10): 6720 - 6729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Butchi, S. Pourciau, M. Du, T. W. Morgan, and K. E. Peterson Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists J. Immunol., June 1, 2008; 180(11): 7604 - 7612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Vercammen, J. Staal, and R. Beyaert Sensing of Viral Infection and Activation of Innate Immunity by Toll-Like Receptor 3 Clin. Microbiol. Rev., January 1, 2008; 21(1): 13 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Adotevi, B. Vingert, L. Freyburger, P. Shrikant, Y.-C. Lone, F. Quintin-Colonna, N. Haicheur, M. Amessou, A. Herbelin, P. Langlade-Demoyen, et al. B Subunit of Shiga Toxin-Based Vaccines Synergize with {alpha}-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity J. Immunol., September 1, 2007; 179(5): 3371 - 3379. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
